Form 4: Agilon Health Director Boosts Stake with 81,000 Share Purchase

Agilon Health Director John William Wulf acquired 81,000 shares of common stock in a pre-planned transaction, increasing his beneficial ownership.

Summary

• John William Wulf, a Director at agilon health, inc. (AGL), purchased 81,000 shares of the company's common stock.
• The transaction occurred on November 12, 2025, at a weighted average price of $0.6289 per share, with prices ranging from $0.6251 to $0.6321.
• Following this purchase, Mr. Wulf beneficially owns a total of 365,857 shares, which includes restricted stock units.
• The acquisition was made pursuant to a Rule 10b5-1(c) pre-planned contract, instruction, or written plan.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal. Insider buying, especially by a director, typically suggests confidence in the company's future, though the transaction being pre-planned (10b5-1) slightly tempers the immediate reactive sentiment.

Positives

• Director John William Wulf's purchase of 81,000 shares signals confidence in agilon health's future prospects.
• The transaction was executed under a Rule 10b5-1 plan, indicating a pre-meditated investment decision rather than a reaction to immediate market events.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

StockSavvy.ai notes that insider buying, particularly by a director, can often be interpreted by the market as a positive signal, suggesting that those closest to the company believe its shares are undervalued or expect positive developments. This transaction occurs within the healthcare services sector, where companies like agilon health focus on value-based care models.

Comparison to Industry Standards

• Insider buying activity, especially by directors, is a common occurrence across all industries. While the size of this particular transaction (81,000 shares) is notable for an individual director, it is not uncommon for executives and board members to increase their holdings, particularly when they perceive a disconnect between market valuation and intrinsic value.
• Compared to similar transactions in the healthcare services industry, a director increasing their stake via open market purchases, even through a 10b5-1 plan, is generally viewed favorably, aligning management's interests with shareholders.

Related Party Transactions

• The transaction involves a director of agilon health, inc. purchasing shares of the company, which is a common form of related party transaction in the context of insider trading regulations.

Stakeholder Impact

• Shareholders may view this insider purchase as a positive indicator, potentially increasing confidence in the company's stock.
• Employees might interpret the director's increased stake as a sign of stability and belief in the company's long-term strategy.

Key Dates

Recommendation

The insider purchase by a director is a positive signal, indicating confidence in the company. However, without additional financial or operational context from other filings, a 'hold' recommendation is prudent. While insider buying is generally favorable, it's one data point and a seasoned investor would seek broader fundamental analysis before a 'buy' recommendation. The pre-planned nature of the transaction also suggests a less opportunistic buy.

Keywords

agilon health, AGL, insider buying, director purchase, stock acquisition, Form 4, beneficial ownership, Rule 10b5-1